1.	Phase III Randomized Study of Vincristine, Doxorubicin, and Dexamethasone (VAD) With Or Without PSC 833 in Relapsed or Refractory Multiple Myeloma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: E-1A95, CAN-NCIC-MY8, CLB-E1A95, EORTC-E1A95/06971, SWOG-E1A95, CAN-NCIC-J1A95, CLB-9596, SWOG-S1A95, NCT00002878, E1A95, MY8
2.	Phase III Randomized Study of Mitoxantrone/Etoposide/Cytarabine (MEC) versus MEC Plus PSC 833 (PSC MEC) in Patients with Recurrent or Refractory Acute Myelogenous Leukemia (AML) Phase: Phase III Type: Treatment Status: Completed Age: 15 to 70 Sponsor: NCI Protocol IDs: E-2995, E2995
3.	Phase III Randomized Study of Intensive Versus Nonintensive Chemotherapy in Older Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Phase: Phase III Type: Treatment Status: Closed Age: 60 and over Sponsor: Other Protocol IDs: LRF-AML14, EU-20016, NCT00005823, ISRCTN62207270
4.	Phase I/II Study of DHAD/VP-16 with PSC 833 as Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (Summary Last Modified 12/95) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 17 and over Sponsor: Protocol IDs: MDA-DM-94052, NCI-V95-0604
5.	Phase I Study of PSC 833 with a Pilot Study of Cytogenetic Risk Adapted Consolidation Followed by a Phase II Pilot Study of Immunotherapy with Interleukin-2 in Previously Untreated Patients with Acute Myelogenous Leukemia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 15 to 59 Sponsor: NCI Protocol IDs: CLB-9621, NCT00002925, CALGB-9621
6.	Phase I/II Study of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer (Summary Last Modified 02/2001) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-97-C-0074C, NCI-T96-0011, T96-0011
7.	Phase II Study of Paclitaxel and Oral PSC 833 (a Nonimmunosuppressive Cyclosporine Analogue) in Persistent or Recurrent Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-126E
8.	Phase II Pilot Study of PSC 833 Modulation of Paclitaxel in Women With Recurrent or Metastatic Breast Cancer (Summary Last Modified 04/2001) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: E-1195, NCT00002826, E1195
9.	Phase II Study of PSC 833 plus Doxorubicin in Metastatic Breast Cancer Refractory to Anthracyclines or Anthracenediones (Summary Last Modified 06/1999) Phase: Phase II Type: Treatment Status: Closed Age: over 18 Sponsor: NCI Protocol IDs: MAYO-943001, NCI-V96-1077
10.	Phase II Randomized Study of Paclitaxel Versus Paclitaxel and PSC 833 in Advanced Breast Cancer (Recurring Less Than 2 Years Since Adjuvant or as Second Line for Advanced Disease) (Summary Last Modified 04/2000) Phase: Phase II Type: Treatment Status: Closed Age: Not specified Sponsor: NCI Protocol IDs: CHNMC-96002, NCI-H97-1137, NCT00002937
11.	Phase II Study of Daunorubicin, Cytarabine, and PSC 833 in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (Summary Last Modified 05/2001) Phase: Phase II Type: Treatment Status: Closed Age: 56 and over Sponsor: NCI Protocol IDs: SWOG-S9918, NCT00004217, S9918
12.	Phase I Study of Paclitaxel with PSC 833 for Advanced Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 to 80 Sponsor: NCI Protocol IDs: NCI-94-C-0119I, NCI-MB-330, NCI-T93-0123N, T93-0123
13.	Phase I Study of Induction and Post-Remission Therapy with ADE (Cytarabine/Daunorubicin/Etoposide) or ADEP (ADE plus PSC 833) Followed by IL-2 for Patients Age 60 and Over with Acute Myeloid Leukemia Phase: Phase I Type: Treatment Status: Completed Age: 60 and over Sponsor: NCI Protocol IDs: CLB-9420, CALGB-9420
14.	Phase I Study of TAX/PSC 833 for Refractory Solid Tumors (Summary Last Modified 02/00) Phase: Phase I Type: Treatment Status: Completed Age: over 18 Sponsor: NCI Protocol IDs: WU-95-0718, NCI-T93-0034O, T93-0034
15.	Phase I Study of Mitoxantrone/Etoposide/PSC 833 in Patients 56 Years of Age and Over with Previously Untreated Acute Myeloid Leukemia (Summary Last Modified 11/98) Phase: Phase I Type: Treatment Status: Closed Age: 56 and over Sponsor: NCI Protocol IDs: SWOG-S9617, SWOG-9617, S9617
16.	Phase I Study of PSC-833 In Combination with Etoposide and Mitoxantrone for Refractory or Relapsed Pediatric Acute Leukemia (Summary Last Modified 04/2002) Phase: Phase I Type: Treatment Status: Completed Age: Under 22 at diagnosis Sponsor: NCI Protocol IDs: POG-9423, CCG-P9423, NCT00002912, P9423
17.	Phase I Study of Chemotherapy Using a Combination of Idarubicin, Cytarabine and Etoposide in Conjunction With the Multidrug Resistance Modulator PSC-833 in Adult Patients With Relapsed or Refractory Acute Leukemia (Summary Last Modified 04/2000) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSGCC-9604, NCI-T96-0066, T96-0066
18.	Phase I Study of Doxorubicin HCl Liposome (Doxil) and PSC 833 in Patients With AIDS-Related Kaposi's Sarcoma and Other Advanced Malignancies (Summary Last Modified 03/2002) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: WU-106, NCI-T97-0073, NCT00003207, T97-0073
19.	Phase I Study of Vinblastine with the P-Glycoprotein Antagonist PSC 833 for Metastatic Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 to 80 Sponsor: NCI Protocol IDs: NCI-92-C-0268K, NCI-T92-0100N, NCI-MB-288